As negotiations with England labor on, Scotland rejects routine use of Vertex's cystic fibrosis drugs
As the battle between Vertex and England’s National Health Service (NHS) continues — the Scottish NHS has rejected two of the drugmaker’s cystic fibrosis medicines.
The US drugmaker has been locked in negotiation with NICE, which has refused to allow the drug in to England’s NHS until Vertex $VRTX offers it a discount on the treatment’s price tag that would compel the agency to look favorably upon its cost-effectiveness. On Monday, the Scottish NHS spurned two of the company’s medicines — Orkambi and Symkevi — for the same reason, to the dismay of thousands of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.